Human Biogenesis receives pre-seed investment from Campus Fund

BusinessWire India

Bangalore (Karnataka) [India]September 12: Campus Fund today announced its investment in Human Biogenesis, a groundbreaking biotech startup developing an innovative sperm detection kit. This pre-seed funding round will support Human Biogenesis in bringing its revolutionary product to market.

Human Biogenesis was founded by Debabrata Mandal and Sachitanand K. Roy, both of whom studied biotechnology at SRM University Chennai. The company is pioneering the development of a unique sperm detection kit that can detect pregnancy risk within 15 minutes to 72 hours after intercourse. This non-invasive test enables women to make informed decisions about the use of emergency contraceptives (ECPs), potentially reducing unnecessary use and associated side effects. The product also has promising applications in forensic cases of sexual harassment.

The global emergency contraception market is expected to reach $37 billion by 2032. In India alone, over 139 million women use modern contraception methods. Human Biogenesis is committed to creating a new product category that addresses a critical need in women's reproductive health and well-being.

Human Biogenesis' sperm detection kit offers several advantages over existing methods: point-of-care testing with results in 10-15 minutes, high accuracy and specificity, user-friendly design that does not require special training, and cost-effectiveness compared to alternatives.

Debebrata said: “At Human Biogenesis, we are driven by the vision of empowering women with greater control over their reproductive health. Our semen detection kit is the result of years of dedicated research and development, inspired by the challenges we have observed in the real world. With the support of the Campus Fund, we are now ready to bring this innovative solution to market, potentially transforming the way women make contraception and reproductive health decisions.”

Darshan Doshi of Campus Fund said: “We are delighted to invest in Human Biogenesis, which embodies exactly the kind of innovation and potential for global impact that Campus Fund is striving for. Their semen detection kit fills a critical gap in women's reproductive health. We are particularly impressed by the founders' vision and technical expertise. Human Biogenesis has the potential to create an entirely new product category and we are excited to support them on this journey.”

The investment will support Human Biogenesis in completing clinical trials, securing patents and preparing for commercial launch. With its potential to revolutionize the contraceptive industry worldwide, Human Biogenesis represents an exciting addition to Campus Fund's portfolio.

(ADVERTISING DISCLAIMER: The above press release has been provided by BusinessWire India. ANI assumes no responsibility for its contents.)